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The present study aimed to investigate the protective effects of salidroside on chronic heart failure 
(CHF) in rats and to explore the underlying mechanisms. One hundred SD rats were randomly divided 
into sham-operated, model, and low-, medium- and high-dose salidroside groups. The CHF model 
was established in later 4 groups. The later 3 groups were intragastrically administrated with 6, 12 and  
24 mg/kg salidroside, respectively, once a day, for continuous 4 weeks. Finally, the serum levels of brain 
natriuretic peptide (BNP) and interleukin 6 (IL-6), cardiac function indexes, and expression levels of 
myocardial cysteinyl aspartate-specific proteinase (Caspase)-3, Caspase-9, matrix metalloproteinase-1 
(MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) protein were determined. Results showed 
that, after treatment, compared with model group, in high-dose salidroside group the heart function 
indexes were significantly improved (P < 0.05), the serum levels of BNP and IL-6 were significantly 
decreased (P < 0.05), the expression levels of myocardial Caspase-3, Caspase-9 and MMP-1 protein were 
significantly decreased (P < 0.05), and the expression level of TIMP-1 protein was significantly increased 
(P < 0.05). In conclusion, salidroside has obvious protective effects on CHF in rats. The mechanisms 
may be related to its regulation of cardiomyocyte apoptosis and ventricular remodelingregulation related 
protein expressions.
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INTRODUCTION
Chronic heart failure (CHF) is a pathophysiological 
syndrome characterized by pulmonary circulation and/
or systemic circulation congestion due to heart pumping 
dysfunction, decreased cardiac output or decreased 
tissue perfusion in the case of normal venous return 
(Al-Mohammad, Mant, 2011). The CHF patients often 
present myocardial remodeling, myocardial cell structure 
change, or increased myocardial cell apoptosis (Distefano, 
Sciacca, 2012). CHF is a common outcome of other end-
stage systemic diseases. With the deepening of population 
aging and rapid increasing of primary diseases such 
as hypertension, coronary heart disease, diabetes and 
hyperlipidemia, the incidence of CHF is obviously rising 
(Cleland et al., 2016). At present, the clinical treatment 
of CHF is mainly based on use of drugs. The traditional 
positive inotropic drugs exert the therapeutic effect 
through improving the hemodynamics, but the long-term 
use of these drugs will increase the mortality of patients. 
China has rich resources in natural medicines. The active 
substances of many natural medicines have the effects 
of improving heart function and resisting myocardial 
ischemia (Yin et al., 2008; Yin et al., 2009). Rhodiola rosea 
L. is the perennial herbaceous plant, which mostly grows 
in the alpine region with altitude of 2-5 km. Rhodiola 
rosea L. contents unique biological active ingredients 
including salidroside, tyrosol, rosavin, polysaccharide, 
flavonoids and saponins. Salidroside is one of the main 
effective components of Rhodiola rosea L.. It has the 
pharmacological effects in resisting hypoxia, promoting 
hematopoietic function, improving microcirculation, 
inhibiting oxidative stress and regulating immune (Zhang 
et al., 2009; Zhang et al., 2013). In clinic, salidroside is 
widely used in prevention and treatment of coronary heart 
disease, hypertension, cerebrovascular disease, climacteric 
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syndrome and other diseases (Han et al., 2015). At present, 
the effect of salidroside on CHF is less reported. It has been 
reported that, the cysteinyl aspartate-specific proteinase 
(Caspase)-3, Caspase-9, matrix metalloproteinase-1 
(MMP-1) and tissue inhibitor of metalloproteinase-1 
(TIMP-1) are involved in the course of heart diseases (Su 
et al., 2003; Sakata et al., 2004; Balakumar, Singh, 2006; 
Picard et al., 2006). This study established the rat CHF 
model, investigated the protective effects of salidroside 
on CHF in rats, and explored the mechanisms related to 
myocardial Caspase-3, Caspase-9, MMP-1 and TIMP-
1 expressions. The objective was to provide a basis for 
application of salidroside to clinical treatment of CHF.
MATERIAL AND METHODS
Animals and treatment
One hundred male Sprague Dawley rats (8 weeks 
of age; 180-200 g; Guangdong Experimental Animal 
Center, Guangzhou, China) were single-cage raised 
under the condition avoiding strong light and noise 
(12/12-h day-night cycle; free to feed and water). The 
rats were randomly divided into sham-operated, model, 
and low-, medium- and high-dose salidroside groups, 20 
rats in each group. The CHF model was established in 
later 4 groups. The rats in low-, medium- and high-dose 
salidroside groups were intragastrically administrated with 
salidroside (purity ≥ 98%; Beijing Suolaibao Technology 
Co. Ltd., Beijing, China), with dose of 6, 12 and 24 mg/
kg, respectively. The sham-operated and model groups 
were intragastrically administrated with equal volume of 
normal saline. The administration was performed once per 
day, for continuous 4 weeks. 
 
Establishment of CHF model in rats
CHF model in rats was established using the coronary 
artery ligation method. After two week of adaptive feeding, 
the rats were anaesthetized by intraperitoneal injection 
of chloral hydrate with dose of 100 mg/kg, followed by 
fixation in supine position and skin preserving on chest. The 
electrocardiogram (ECG) electrode was subcutaneously 
embedded in the right upper limb and left lower limb, and 
the normal lead II ECG was recorded. The left fourth-fifth 
intercostal chest skin was cut open, and the pectoral was 
bluntly separated. The chest was opened using forceps, and 
the heart was exposed. The right chest was gently pressed, 
and the heart was gently squeezed out of the thoracic 
cavity. The threading was performed at the position 3 mm 
from the initial section of left anterior descending coronary 
artery between the pulmonary artery cone and left atrial 
appendage. Then, the heart was placed to the thoracic 
cavity. After squeezing out the air, the thoracic cavity was 
closed, and the spontaneous breathing was restored. After 
stabilization for 10 min, the coronary artery was ligated. The 
ECG changes were observed and recorded. The significant 
elevation of the ST segment in ECG presented successful 
establishment of acute myocardial infarction model. The 
wound was sutured, followed by using penicillin to prevent 
the infection. After 4 weeks from surgery, the cardiac 
functions were detected using color echocardiography. 
The ejection fraction less than 45% was considered as a 
sign of CHF. The rats with death or failure to meet CHF 
criteria were excluded. The sham-operated group received 
the surgery the same with other 4 groups, excepting the 
coronary artery ligation.
Detection of serum brain natriuretic peptide and 
interleukin 6 levels of rats
At the end of treatment, 10 ml of femoral vein blood 
was taken from the rats. The serum brain natriuretic peptide 
(BNP) and interleukin 6 (IL-6) levels were determined 
using radioimmunoassay method. The procedures were in 
accordance to the instructions of kits (Shanghai Sangon 
Biological Engineering Technology And Service Co., Ltd., 
Shanghai, China).
 
Detection of cardiac function of rats
After anaesthetizing using 10% chloral hydrate, 
the rats were fixed in supine position. The right carotid 
artery was separated. The ventricular catheter was inserted 
into the left ventricle through the right carotid artery, 
and was connected to the biological signal recorder to 
determine the left ventricular systolic pressure (LVSP), left 
ventricular end diastolic pressure (LVEDP) and maximum 
left ventricular systolic/diastolic rate (±dp/dtmax).
 
Determination of protein expressions related 
to cardiomyocyte apoptosis and ventricular 
remodelingregulation 
The rats were executed, and the heart of was taken. 
The myocardial tissue was homogenized, and the protein 
was extracted. The expressions levels of cardiomyocyte 
apoptosis related protein Caspase-3 and Caspase-9, and 
ventricular remodelingregulation related protein MMP-1 
and TIMP-1 in myocardial tissue were determined using 
western blot assays (Liu, Zhang, Li, 2011; Jin et al., 2014). 
The procedures were in accordance to the instructions of 
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kits (Beijing Zhongshan Golden Bridge Biotechnology 
Co., Ltd., Beijing, China).
Statistical analysis
The data were presented as mean±standard deviation, 
and were analyzed using SPSS 20.0 software (SPSS 
Inc., Chicago, IL, USA). Comparisons among different 
groups were performed using the single-factor analysis 
of variance test with SNK-q test. P < 0.05 presented 
statistically significant.
RESULTS
General situation and death of rats
After establishment of CHF model, the rats in model 
group presented nose and lip cyanosis, pallor of extremities, 
rough color and yellowing, abdominal hair shedding, lags 
in response, reduced feed consumption, slow action and 
other CHF symptoms, which were gradually aggravated 
with time prolonging. During the treatment duration, the 
CHF symptoms of rats in salidroside groups were gradually 
alleviated, especially in high-dose salidroside group. At the 
end of treatment, the CHF symptoms of rats in high-dose 
salidroside group were obviously alleviated, with good 
blood flow, white and lustre hair, sensitive response, and 
basically normal food taking and activities. In model group 
there were 6 rats with death, with mortality rate of 30%. No 
rat died in each other group. 
Salidroside improving the cardiac function of CHF 
rats
As shown in Table I, compared with sham-operated 
group, in model group the LVEDP was significantly 
increased (P < 0.05), and the LVSP, +dp/dtmax and -dp/
dtmax were significantly decreased, respectively (P < 0.05). 
Compared with model group, the LVSP and +dp/dtmax in 
middle- and high-dose salidroside groups, and the -dp/
dtmax in 3 salidroside groups were significantly increased, 
respectively (P < 0.05). The LVEDP in middle- and high-
dose salidroside groups was significantly decreased, 
respectively (P < 0.05).
Salidroside decreasing the serum BNP and IL-6 
levels in CHF rats
Compared with sham-operated group, the serum 
BNP and IL-6 levels in model group were significantly 
increased, respectively (P < 0.05). Compared with model 
group, the serum BNP level in high-dose salidroside group 
was significantly decreased (P < 0.05), and serum IL-6 
levels in middle- and high-dose salidroside groups were 
significantly decreased, respectively (P < 0.05) (Table II).
Salidroside regulating myocardial Caspase-3 and 
Caspase-9 protein expressions in CHF rats
As shown in Figure 1, compared with sham-operated 
group, the expression levels of myocardial Caspase-3 
TABLE I - Effects of salidroside on cardiac function of rats
Group LVSP (kPa) LVEDP (kPa) +dp/dtmax (kPa/s) -dp/dtmax(kPa/s)
Sham-operated 141.8±23.45 0.08±0.03 821.46±100.72 765.21±121.73
Model 72.11±10.23* 0.62±0.21* 321.05±91.94* 267.33±44.92*
Low-dose salidroside 80.91±21.02* 0.55±0.15* 332.19 ±73.04* 198.04±35.03*#
Middle-dose salidroside 111.27±12.49*#& 0.18±0.07*#& 682.01±118.29*#& 615.03±178.03*#&
High-dose salidroside 127.81±18.56#&% 0.11±0.05#&% 762.47±120.21#& 661.04±156.22#&
*P < 0.05 compared with sham-operated group; #P < 0.05 compared with model group; &P < 0.05 compared with low-dose salidroside 
group; %P < 0.05 compared with middle-dose salidroside group. LVSP, left ventricular systolic pressure; LVEDP, left ventricular 
end diastolic pressure; dp/dtmax, maximum left ventricular systolic/diastolic rate.
TABLE II - Effects of salidroside on serum BNP and IL-6 levels 
in rats
Group BNP (× 109 g/L) IL-6 ((pg/mL)
Sham-operated 444.93±103.52 24.32± 2.94
Model 598.23±126.92* 33.52±3.87*
Low-dose salidroside 553.01±138.27* 32.72±2.96*
Middle-dose salidroside 497.34±128.03& 28.04±3.21*#&
High-dose salidroside 483.67±78.03#& 25.16±2.64#&
*P < 0.05 compared with sham-operated group; #P < 0.05 
compared with model group; &P < 0.05 compared with low-
dose salidroside group. BNP, brain natriuretic peptide; IL-6, 
interleukin 6.
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and Caspase-9 protein in model group were significantly 
increased, respectively (P < 0.05). Compared with model 
group, the expression level of Caspase-3 protein in high-
dose salidroside group was significantly decreased (P 
< 0.05), and the expression levels of Caspase-9 protein 
in middle- and high-dose salidroside groups were 
significantly decreased, respectively (P < 0.05).
Salidroside regulating myocardial MMP-1 and 
TIMP-1 protein expressions in CHF rats
Compared with sham-operated group, in model 
group the expression level of myocardial MMP-1 protein 
was significantly increased (P < 0.05), and the expression 
level of TIMP-1 protein was significantly decreased (P < 
0.05). Compared with model group, the expression levels 
of MMP-1 protein in middle- and high-dose salidroside 
groups were significantly decreased, respectively (P 
< 0.05), and the expression levels of TIMP-1 protein 
in 3 salidroside groups were significantly increased, 
respectively (P < 0.05) (Figure 2).
DISCUSSION
Salidroside has the anti-hypoxia, anti-myocardial 
ischemia, anti-myocardial apoptosis, anti-oxidative stress, 
FIGURE 2 - Effects of salidroside on myocardial MMP-1 and TIMP-1 protein expressions in rats. *P < 0.05 compared with sham-
operated group; #P < 0.05 compared with model group; &P < 0.05 compared with low-dose salidroside group; %P < 0.05 compared with 
middle-dose salidroside group. 1: Sham-operated group; 2: Model group; 3: low-dose salidroside group; 4: middle-dose salidroside 
group; 5: high-dose salidroside group. MMP-1, matrix metalloproteinase-1; TIMP-1, tissue inhibitor of metalloproteinase-1.
FIGURE 1 - Effects of salidroside on myocardial Caspase-3 and Caspase-9 protein expressions in rats. *P < 0.05 compared with 
sham-operated group; #P < 0.05 compared with model group; &P < 0.05 compared with low-dose salidroside group; %P < 0.05 
compared with middle-dose salidroside group. 1: Sham-operated group; 2: Model group; 3: low-dose salidroside group; 4: middle-
dose salidroside group; 5: high-dose salidroside group. Caspase-3, cysteinyl aspartate-specific proteinase-3; Caspase-9, cysteinyl 
aspartate-specific proteinase-9.
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anti-nerve cell damage, immunity regulation and sleep 
improvement effects, and is widely used in the prevention 
and treatment of hypertension, stroke, neurasthenia and 
other diseases (Huang et al., 2015). Studies (Zheng et al., 
2017; Sun et al., 2018) have confirmed that, salidroside can 
inhibit the apoptosis of vascular endothelial cells, reduce 
the expression of vascular endothelial growth factor in 
atherosclerotic plaques, and inhibit the angiogenesis, 
thereby blocking the formation of atherosclerosis. In 
addition, salidroside can block the mitochondrial pathway 
to reduce the apoptosis of ischemic cardiomyocytes, 
and protect the heart from reperfusion injury (Wu et al., 
2009). However, whether salidroside plays a role in CHF 
and its specific mechanisms remain to be further studied. 
In this study, the CHF of rat model was established, and 
the effects of salidroside on CHF and the underlying 
mechanisms were investigated. Results showed that, after 
4 weeks of treatment, the rats in model group presented 
obvious CHF symptoms. Compared with model group, 
the CHF symptoms in salidroside groups were obviously 
alleviated. The mortality rate of rats in salidroside groups 
was significantly lower than model group. In addition, 
the heart function indexes in model group were obviously 
deteriorated. Compared with model group, in salidroside 
group the heart function indexes of rats were significantly 
improved. This indicates that, salidroside has obvious 
protective effects on CHF in rats.
BNP is a polypeptide hormone composed of 32 
amino acids. It is mainly synthesized and secreted by 
the ventricle. When the ventricular volume load and 
wall tension change, the amount of BNP produced by 
ventricle increases. Therefore, the concentration of BNP 
in blood can directly reflect the function of ventricle 
(Kallistratos et al., 2008). It is reported that, the plasma 
concentration of BNP in CHF patients is higher than 
that in normal people, and it is positively related to the 
severity of heart failure (Mowla, Bustami, 2006). IL-6 is 
a cytokine secreted by activated macrophages, and it has 
a wide range of biological effects in the body. On the one 
hand, IL-6 has the antiviral, antibacterial and antiparasitic 
function (Fostok et al., 2009). On the other hand, IL-6 
can cause serious damage to the body by participating 
in some serious pathophysiological states such as septic 
shock and malignant fluid (Martin et al., 1997). Previous 
study (Tsutamoto et al., 1998) has shown that, IL-6 plays 
wide pathophysiological roles in the development of heart 
failure. The IL-6 concentration in heart failure patients 
is significantly higher than that of the normal control 
group, and the IL-6 level is positively correlated with 
cardiac function level, that is, the more serious the heart 
failure is, the higher the IL-6 concentration is. Results of 
this study showed that, compared with sham-operated 
group, the serum BNP and IL-6 levels in model group 
were significantly increased, respectively. Compared 
with model group, the serum BNP level in high-dose 
salidroside group was significantly decreased, and serum 
IL-6 levels in middle- and high-dose salidroside groups 
were significantly decreased, respectively. This indicates 
that, salidroside can alleviate CHF in rats by regulating 
the level of neuroendocrine cytokines.
Apoptosis is a process of automatic life ending 
which is controlled by the internal genetic mechanism 
under certain physiological or pathological conditions. 
Apoptosis is involved in the ventricular remodeling, and 
plays an important role in the evolution of heart failure 
(Palojoki et al., 2001). The occurrence of apoptosis is 
mediated by the exogenous and endogenous pathways 
which exert the functions by activating Caspases. In 
Caspases family, Caspase-3 is the most important 
apoptosis protease in downstream of apoptotic cascade 
reaction. Caspase-9 is in the upstream of apoptotic cascade 
reaction. Caspase-9 is activated by the apoptosome formed 
under the promotion of various apoptotic factors, and acts 
with Caspase-3, thus executing the apoptotic program 
(Cowan, Roskams, 2004). In this study, compared with 
sham-operated group, the expression levels of Caspase-3 
and Caspase-9 protein in myocardial tissue of rats in 
model group were significantly increased, respectively. 
Compared with model group, the expression level of 
Caspase-3 protein in high-dose salidroside group was 
significantly decreased, and the expression levels of 
Caspase-9 protein in middle- and high-dose salidroside 
groups were significantly decreased, respectively. This 
indicates that, Caspase-3 and Caspase-9 are involved in 
the CHF in rats, and salidroside can down-regulate the 
myocardial Caspase-3 and Caspase-9 protein expressions 
in CHF rats, thus exerting the protection effect.
Ventricular remodeling is the basic pathological link 
of occurrence and development of CHF, and the change 
of extracellular matrix is an important part of ventricular 
remodeling. Matrix metalloproteinases are the most 
important enzymes in the degradation of extracellular 
matrix of myocardium, and are the most important 
driving force for ventricular remodeling (Sakata et al., 
2004). It has been shown that, the activation of MMP-1 
plays an important role in cardiac remodeling induced 
by extracellular matrix remodeling. TIMP-1 is a specific 
inhibitor of MMP-1. The balance between MMP-1 and 
TIMP-1 is important for maintaining the stability of 
cardiac collagen metabolism (Picard et al., 2006). Results 
of this study showed that, compared with sham-operated 
group, in model group the expression level of MMP-1 
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protein in myocardial tissue of rats was significantly 
increased, and the expression level of TIMP-1 protein 
was significantly decreased. Compared with model group, 
the expression levels of MMP-1 protein in middle- and 
high-dose salidroside groups were significantly decreased, 
respectively, and the expression levels of TIMP-1 protein 
in 3 salidroside groups were significantly increased, 
respectively. This indicates that, MMP-1 and TIMP-1 
are also involved in CHF in rats, and the protection effect 
of salidroside is related to its regulation of MMP-1 and 
TIMP-1 protein expressions in myocardial tissue.
CONCLUSION
Salidroside has obvious protective effects on CHF 
in rats. The mechanism may be related to its regulation of 
cardiomyocyte apoptosis protein Caspase-3 and Caspase-9 
expressions and ventricular remodelingregulation protein 
MMP-1 and TIMP-1 expressions in myocardial tissue. 
This study has provided an experimental basis for the 
application of salidroside to clinical treatment of CHF. 
This study still has some limitations. The dose-effect 
relationship of salidroside on CHF is not very clear, 
and more salidroside doses should be adopted in next 
studies. In addition, whether there are correlations among 
these proteins and whether there are other mechanisms 
of salidroside in alleviating CHF should be further 
investigated.
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